E2 ModerateModerate confidencePEM ?Cross-SectionalPeer-reviewedMachine draft
Medication use and symptomology in North American women with myalgic encephalomyelitis/chronic fatigue syndrome.
Pochakom, Angela, MacNevin, Gillian, Madden, Robyn F et al. · Frontiers in medicine · 2025 · DOI
Quick Summary
This study surveyed 135 women with ME/CFS in North America to understand what medications they use and how these relate to their symptoms and daily functioning. Most participants were taking an average of 3 medications for ME/CFS-related symptoms, with pain medications being the most common, followed by psychiatric and immune-related medications. Interestingly, the study found a U-shaped pattern: both people using very few medications and those using many medications reported lower physical functioning, while moderate medication use was associated with better functioning.
Why It Matters
This study provides the first systematic characterization of real-world medication use patterns in ME/CFS patients, offering validation that patients are managing multiple complex symptoms through diverse pharmacological approaches. Understanding these patterns helps clinicians recognize common treatment strategies and may inform more evidence-based, individualized therapeutic protocols rather than the current trial-and-error approach that many patients endure.
Observed Findings
- 68.6% of participants reported taking medications specifically for ME/CFS symptoms
- Analgesic medications were most commonly used (31.7%), followed by psychotropic medications (26.4%), and immune-related medications (10.6%)
- Participants used an average of 3.0 ME/CFS-related medications, with higher usage in US participants compared to Canadian participants
- A U-shaped relationship was found between number of medications and self-reported physical functioning (hours/week), with moderate medication use associated with better functioning
- No significant correlation existed between number of medications used and disease duration, age, or age at diagnosis
Inferred Conclusions
- ME/CFS treatment in women relies on diverse pharmacological strategies reflecting the heterogeneity of symptoms, with no single standardized approach
- Current medication patterns represent a trial-and-error therapeutic landscape, suggesting an urgent need for evidence-based treatment guidelines tailored to distinct symptom profiles
- The U-shaped medication-function relationship suggests that both undertreatment and polypharmacy may be suboptimal, pointing toward a potential therapeutic "sweet spot" for medication use
- Gastrointestinal symptoms appear to drive different medication choices compared to other symptom clusters, indicating that symptom-specific phenotyping may help guide treatment selection
What This Study Does Not Prove
This study does not establish which medications are most effective or safe for ME/CFS, as it only documents what patients are taking, not treatment outcomes. The U-shaped relationship between medication use and functioning is correlational—it cannot prove that using fewer or more medications causes worse functioning; patients with more severe disease may use more medications or have lower functioning independent of medication effects. The findings apply only to North American women and may not generalize to men or other populations.
Tags
Symptom:Cognitive DysfunctionPainFatigueSensory Sensitivity
Method Flag:PEM Not DefinedWeak Case DefinitionNo ControlsSmall SampleExploratory OnlySex-Stratified